EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

Tristan V M Bruijn iD, Alexandre O Gérard, Maëlys Labat, Zoe Apalla iD, Wouter van Binsbergen, Dimitra Koumaki iD, Valerian Rivet, Frederic Dezoteux iD, Damien Giacchero, Michael R Ardern-Jones, Kara Heelan, Jesse P Hirner und 6 weitere

Journal of the European Academy of Dermatology and Venereology · 2026-10 · 40 (10) · 1702-1712

DOI: 10.1111/jdv.70512 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 08.06.2026. Verfasst von Tristan V M Bruijn und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Amsterdam UMC, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Fasciitis, Immune Checkpoint Inhibitors, Eosinophilia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

With the widespread use of immune checkpoint inhibitors (ICI), rare cutaneous immune‐related adverse events (cirAEs), including ICI‐induced eosinophilic fasciitis (ICI‐EF), are increasingly encountered. However, data on its clinical presentation and optimal therapeutic approaches remain sparse.

Objectives

This study aimed to further characterize the clinical features and outcomes of ICI‐EF.

Methods

This retrospective observational study analysed clinical features, treatment strategies and outcomes of ICI‐EF cases from EADV Task Force‐affiliated dermatology departments, complemented by cases from the current available literature and two international pharmacovigilance databases. Patient demographics, clinical characteristics, diagnostics, treatment and follow‐up data were extracted from the medical records and databases.

Results

We present 121 ICI‐EF cases from the EADV Task Force ( n = 15), FPVD ( n = 21), VigiBase® ( n = 45) and the literature ( n = 40). The most prevalent underlying malignancy in all groups was melanoma (50%), with PD‐1 inhibitor monotherapy (81%) being the predominant offending drug class. The median time to ICI‐EF onset was 10 months (IQR 6.8–16.3; range < 1–36). Detailed clinical information was available for 76 of the 121 cases (63%), revealing a highly variable clinical presentation. Treatment primarily involved ICI discontinuation (83%) and systemic corticosteroids (80%), followed by methotrexate (41%), intravenous immunoglobulins (12%) and mycophenolate mofetil (13%), resulting in the partial or complete resolution of ICI‐EF symptoms (66%).

Conclusions

ICI‐EF is a rare heterogeneous cirAE with varying clinical features and significant morbidity. Early recognition and timely treatment are key to ensuring ICI continuation and preserve oncologic outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FasciitisImmune Checkpoint InhibitorsEosinophiliaHumansFemaleRetrospective StudiesMalePharmacovigilanceMiddle AgedAgedMelanomaAdult

Stichwörter der Autor:innen

anti‐CTLA‐4anti‐PD‐1cancerdrug eruptioneosinophilic fasciitisimmune checkpoint inhibitorimmune‐related adverse eventmelanoma

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Amsterdam UMC, Amsterdam, The Netherlands.
  • Department of Dermatology, The Netherlands Cancer Institute-Antoni Van Leeuwenhoek, Amsterdam, The Netherlands.
  • Department of Clinical Pharmacology, Université Côte d'Azur, University Hospital Centre of Nice, Nice, France.
  • Laboratory of Molecular Physio Medicine (LP2M), UMR 7370, CNRS, Université Côte d'Azur, Nice, France.
  • Saint Louis Régional Pharmacovigilance Centre, Clinical Investigation Centre (INSERM CIC 1427), Saint-Louis Hospital, Paris, France.
  • Second Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.

ORCID-Profile: Tristan V M Bruijn, Zoe Apalla, Dimitra Koumaki, Frederic Dezoteux, Ander Mayor, Vincent Sibaud, Yannick S Elshot

Zitieren

APA

Bruijn, T. V. M., Gérard, A. O., Labat, M., Apalla, Z., Binsbergen, W. V., Koumaki, D., Rivet, V., Dezoteux, F., Giacchero, D., Ardern-Jones, M. R., Heelan, K., Hirner, J. P., Mayor, A., Labots, M., Starink, M. V., Laken, C. J. V., Sibaud, V., & Elshot, Y. S. (2026). Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study. Journal of the European Academy of Dermatology and Venereology, 40(10), 1702-1712. https://doi.org/10.1111/jdv.70512

Vancouver

Bruijn TVM, Gérard AO, Labat M, Apalla Z, Binsbergen WV, Koumaki D, et al. Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study. Journal of the European Academy of Dermatology and Venereology. 2026;40(10):1702-1712. doi:10.1111/jdv.70512

BibTeX
@article{Bruijn2026,
  author = {Bruijn, Tristan V M and Gérard, Alexandre O and Labat, Maëlys and Apalla, Zoe and Binsbergen, Wouter van and Koumaki, Dimitra and Rivet, Valerian and Dezoteux, Frederic and Giacchero, Damien and Ardern-Jones, Michael R and Heelan, Kara and Hirner, Jesse P and Mayor, Ander and Labots, Mariette and Starink, Markus V and Laken, Conny J van der and Sibaud, Vincent and Elshot, Yannick S},
  title = {Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  volume = {40},
  number = {10},
  pages = {1702--1712},
  doi = {10.1111/jdv.70512}
}
Kostenlos starten →